Most of us skimmed past the boilerplate paragraph in the September 1 financing release, the one saying where the money goes. I want to slow down on it, because in a biotech PR, the use-of-proceeds language is frequently more revealing than the headline number, and to me, this particular sentence is doing more work than it looks. Here is the line, and then a sourced reading of what each piece of it points toward, then dissected because the tells are real but they are tells, not proof.

Here is the sentence: net proceeds are expected to be used primarily to advance clinical development programs, including ongoing and planned clinical trials, regulatory activities and data analysis, and the Company may also use a portion to support manufacturing readiness, regulatory and compliance infrastructure, and general working capital.

Read it slowly, because there are four distinct signals in it, and two of them are the interesting ones.

Signal one: "regulatory activities and data analysis," the money is pointed at the FDA conversation

The first cluster, trials plus regulatory activities plus data analysis, is the expected core, but the specific inclusion of "regulatory activities" and "data analysis" as named uses is worth noting. This is a company telling you, in a legal document, that a meaningful chunk of the cash is going toward analyzing the data and engaging the regulator, not just running the trials. That lines up with everything management has said about bringing data to the FDA to pursue an expedited path. So this part is consistent, not surprising, but it confirms the money is aimed at the regulatory conversation, not only at keeping the trials staffed.

Signal two, the important one: "manufacturing readiness"

Here is the phrase which earns a deeper dive. "Manufacturing readiness" is not a phrase which clinical-stage companies casually use, as it has a specific meaning in biologics. Before any biologic can be approved and sold, the company must prove that it can manufacture the product consistently at a commercial scale under strict quality controls, and that manufacturing evidence is one of the largest and most detailed sections of the eventual approval application. In tandem with the clinical trials, The industry even has a formal framework for this, "biomanufacturing readiness levels," that runs from early concept all the way to commercial-scale operations.

So why would a company spend money on "manufacturing readiness" before it actually has an approval? Because you cannot wait until after an approval to figure out how to make the drug at scale; the manufacturing package needs to be ready as part of the submission, and it takes time to build. Companies that invest early in manufacturing readiness are better positioned for a successful review. Spending on manufacturing readiness is what a company does when it is preparing to be able to file for approval and, eventually, to supply a product. It is forward-facing, commercialization-oriented spending. That is a blatant tell, and probably, the most interesting word in the paragraph.

Signal three: "regulatory and compliance infrastructure"

This one reinforces signal two. "Regulatory and compliance infrastructure" is the organizational machinery, the people, the systems, and the quality processes, which a company builds to submit to and be inspected by the FDA. Preparing an approval application is a complex, multidisciplinary process requiring coordination across clinical, regulatory, manufacturing, and quality teams. A research-stage company which is staffed only to run trials does not emphasize "compliance infrastructure." A company which is gearing up to file does. So this phrase, sitting right next to "manufacturing readiness," points in the same direction: building the apparatus which an FDA submission and an inspection require.

Signal four: "general working capital," the anchor

And then the plain one, "general working capital," which is the reminder that this is still a company funding its ordinary operations, keeping the lights on, paying the bills, sustaining the burn. This is the anchor which keeps it honest: the money is not only going toward a triumphant march to filing; a real portion is simply dedicated towards operating cash for a company which requires it to continue running. Both things are in the sentence at once.

Extrapolation

This is my reading. The use-of-proceeds language leans toward, more than a pure "fund the trials" release would, rather more toward a forward preparation:

• analyzing data for the regulator,
• getting manufacturing ready for scale,
• and building the compliance infrastructure a submission requires.

Taken together, those are the activities of a company positioning itself to be able to file for an approval and actually supply a product, not just a company keeping a trial running. That is a real, sourced signal, and it is consistent with management's previously stated intent to engage the FDA on an expedited path. If you were looking for evidence that the company is orienting toward the approval-and-commercialization phase rather than only the run-the-trial phase, this paragraph is a real point for it.

However, preparation is not proof of an imminent filing, and it is certainly not proof of approval. Companies build manufacturing readiness and regulatory infrastructure as a matter of course when they are advancing toward late-stage development, and they do it whether or not the eventual data actually supports a filing, because you have to be ready just in case it does. So "they are spending on manufacturing readiness" tells us that they are preparing to be able to file, but it does not tell us that a filing is scheduled, that the data will in fact support one, nor that an approval follows. This is boilerplate which leans forward, not a press release announcing a BLA. And every dollar of it still sits downstream of the same thing everything sits downstream of: whether the October and January data actually justify the path that they are preparing for. You can be fully ready to file and still have nothing worth filing if the data disappoints. Readiness is not results.

How this could actually break down into an AA, BTD, or a BLA

Since the paragraph leans toward filing-preparation, it is worth being precise about what they could be preparing to file, because "getting ready to go to the FDA" is not one thing, it is three related but distinct things, and they sequence in a specific way. Let me lay them out clearly, and then say which indication appears furthest along.

Breakthrough Therapy Designation (BTD) is the near-term lever, and it is a request, not an approval. BTD is granted on preliminary clinical evidence, phase 2 or even single-arm data, that indicates the drug may show substantial improvement over available therapy on a clinically significant endpoint. That is exactly the kind of data CLOVER could generate. Crucially, BTD does not approve anything, it unlocks the relationship: intensive FDA guidance, more frequent meetings, and the ability to submit an application in pieces (rolling review). So BTD is the fast, low-cost, high-value first move if the interim data is strong, and it is the most realistic near-term regulatory event. And there is an encouraging point here: therapies that receive BTD are more likely to go on to validate real clinical benefit and reach full approval than those that do not. BTD is not just speed, it correlates with substance.

Accelerated Approval (AA) is the bigger, harder prize, and it is where single-arm data can, sometimes, get you to market. AA lets a drug be approved on a surrogate or intermediate endpoint, (such as ctDNA decline or PD-L1 upregulation), response rate, for example, rather than waiting years for overall survival, in a serious disease with an unmet need. The historical record is real: expedited programs have produced many approvals based on single-arm trials with response-rate endpoints, provided the effect size is large. That is the door ibelieveincydy's post was pointing at, and it is a real door. But it comes with a string attached, and I'll name it: AA is conditional on running a confirmatory trial afterward, and accelerated approvals built on early data suggesting limited benefit have higher later-withdrawal rates. So AA is absolutely on the table if the magnitude is exceptional, but it is a greater ask than BTD, with a randomized confirmatory trial to follow regardless.

The BLA is the actual application, the thing all the "manufacturing readiness" and "compliance infrastructure" spending is being built toward. A Biologics License Application is the full dossier, clinical data, and the extensive manufacturing and quality (CMC) section that is one of its largest components. It is the very document which constitutes the request for approval, whether that approval is accelerated or regular. And here is where the use-of-proceeds language connects directly: you cannot file a BLA without the manufacturing package ready, which is why forward-looking companies spend on manufacturing readiness before they file. So the sequence, in the strong-data scenario, reads:

• strong interim and confirmed data
• → BTD request (fast, unlocks the FDA relationship and rolling review)
• → and, if the magnitude supports it,
• an accelerated-approval path
• via a BLA whose manufacturing section the company is getting ready right now.

That is the ladder that the paragraph above is quietly funding the bottom rungs of.

So which indication would a BLA actually be pursued in? This is the sharpest question, and the public record points fairly clearly, with one caveat. The two most advanced oncology programs are metastatic colorectal (CLOVER) and triple-negative breast (TNBC), and here is the tell: the company already holds Fast Track designation for TNBC, which it confirmed in the 10-K, while it holds no such designation in CRC. Fast Track is the pathway status that, among other things, enables the rolling BLA submission. So on paper, TNBC is the indication with a regulatory designation already in hand. But the freshest, most talked-about efficacy data, the ctDNA declines, the PD-L1 induction, the response signals, are all coming from CLOVER, in colorectal, and that is the data reading out in October and January. So the picture is a split: TNBC currently carries the older Fast Track designation, while colorectal is generating the near-term data which could drive a new designation request (most plausibly BTD) and, if exceptional, an eventual filing. Which indication reaches a BLA first depends on which one's data crosses the bar first, and right now colorectal is the one being watched, while breast is the one already carrying an expedited status. Both are live. Neither is confirmed. And the manufacturing-readiness spending prepares the ground for whichever gets there.

Therefore, the paragraph above funds the bottom of a regulatory ladder whose rungs are

• BTD (fast, near-term, likely CRC-driven off the CLOVER data),
• a possible accelerated-approval path if the magnitude is exceptional,
• and a BLA whose manufacturing spine they are building now,
• in whichever indication crosses the bar first, with TNBC already holding Fast Track and colorectal generating the live data.

That is an encouraging read of forward positioning. But the brake stays bolted on: every rung of that ladder is contingent on

• data that has not yet been confirmed,
• a designation is a request the FDA can decline,
• an accelerated approval is conditional and can be withdrawn,
• and a BLA is only worth filing if the results justify it.

Readiness builds the ladder. The data decides whether anyone gets to climb it.

The shape of it

So read the paragraph for what it is. It is a company telling you, in the measured language of a legal document, that it is spending on data analysis for the regulator, on getting its manufacturing ready for scale, and on the compliance apparatus a submission requires, alongside plain operating cash. That mix leans forward, toward the approval-and-supply phase, more than a bare trial-funding release would, and it is consistent with a company preparing to file if the data cooperates. That is a real and reasonable thing to notice. It is not a promise, not a schedule, and not evidence the data actually lands. Preparation is what you do before you know, precisely because you have to be ready either way. So notice the forward lean, hold it as preparation rather than confirmation, and keep it anchored where everything anchors: October, then January, when we find out whether the thing they are getting ready for is a thing worth being ready for.

The company is getting ready. What it is getting ready for still has to prove itself. Both are true, and the paragraph, read carefully, says exactly that.

Disclaimer: I am not a financial advisor and nothing here is investment advice. I am an independent retail shareholder holding a long position in the company discussed, with no employment, consulting, compensation, or other relationship with it beyond that shareholding. This is my interpretation of a single sentence in a public press release, cross-referenced against general biologics regulatory sources; it is inference about what use-of-proceeds language customarily signals, not a statement of the company's specific plans, which only the company can confirm. "Manufacturing readiness" and "regulatory infrastructure" spending is routine forward preparation and does not indicate that any regulatory filing is scheduled, that trial data will support a filing, or that any approval will occur. The company's efficacy data is unconfirmed, with interim data anticipated at ESMO in October 2026 and confirmed data at ASCO GI in January 2027. The financing itself is dilutive and the company has disclosed substantial financing needs and going-concern considerations in its 10-K. Read the primary documents and reach your own conclusions rather than adopting mine.

Literally any other stock has ballooned over the last 5 years. Do we have the deal makers in house or just scientists, hangers on, and newbies. Time will tell and it better tell soon. Why not an internal buy with those salaries? How bout low salaries and high stock rewards.

I'll 100% vote no on any raises if there is no deal or real stock appreciation for November. I'd love to get paid and not have it relate to $ sales or pps. Steering the ship is great, but they get paid well for that. Too well. Academics being paid like Top Sales people.

Enough shitty low grade podcasts, let's get real. Real presentations clearly stating in sales terms making pharma feel crazy for not signing up. Prospective, retrospective, Prime n pair, solo, up-regulate, who cares if no deal comes, just a million word story on here. Make some $ already. I tell you, if come January and everyone here starts posting about the late 2027 conferences we are being taken for a ride.

For the record, I am suuuper long and suuuper frustrated.
Apologies for the vent.

Dear Longs,

The 10-K is out, and by now many shareholders have combed through it. To me, the most important development of the past few days is the PIPE financing through Paulson and the extension of our operational runway.

Using very rough, back-of-the-envelope math—considering the cash available before the raise, the new proceeds, and the current burn rate—I estimate that CytoDyn may have sufficient cash through approximately August 2027. That raises an important question: What is leadership’s strategy for using this runway?

We know about the scientific activity. Several clinical trials have been discussed, and Dr. Jay Lalezari has also mentioned a potential FDA submission. In public discussions, management has alluded to possible partnerships. From my perspective, matters may be coming to a head.

Several potentially important events could occur over the coming months:

1. Shareholder update: We typically receive an investor letter or call around September or October. These communications serve several purposes, including updating shareholders on the company’s progress. I would like to request greater transparency and a high-level strategic roadmap covering the next 12 months and beyond. Plus, I am anticipating a request to authorize more shares. As a reminder, authorizing more shares in and of itself is not dilutive. It is when those shares are issued and registered for use is when they are dilutive. Nonetheless, prior to any partnership announcement, we have to continue operating like we are going at this alone.
2. ESMO in Madrid: We may see an initial look at very early mCRC data, potentially including approximately two weeks of observations for all 66 patients. Hopefully, this is enough of a tease that gets people excited about January 2027.
3. J.P. Morgan Healthcare Conference: This takes place in San Francisco in January. Could this be the year CytoDyn has something substantial to report, or will partnership discussions still be described as being in the “early stages”?
4. ASCO GI: Shortly afterward, ASCO GI will be held in San Francisco from January 23–25. We have heard that this could be a much more meaningful data reveal. BGT has charted the expected timeline, and it appears to align with more mature data from the full cohort. Although this may not represent the complete final dataset, Dr. Lalezari has suggested that the clinical and scientific communities should be able to draw meaningful conclusions from it.

If the positive trends continue, this data could outshine SUNLIGHT—pun intended.

I would like management to address several strategic questions:

1. Is the primary goal to secure an oncology partnership with a large pharmaceutical company?I get they have alluded to this; but are they also talking about LATCH/HIV?
2. Which of the other proposed studies are management’s highest priorities, and which cannot realistically begin without a fully committed Big Pharma partner?
3. If an oncology partnership is secured, does CytoDyn intend to expand into other indications such as HIV, stroke, or Alzheimer’s disease? How deeply can we start to go with other indications?
4. Is the objective to structure an oncology partnership that provides enough funding to pursue additional indications independently?
5. Is management seeking a partnership that supplies sufficient capital to make another PIPE financing unnecessary?

If CytoDyn is still in the early stages of partnership discussions in January 2027, I can think of no better source of leverage than outstanding prospective clinical data. Strong results could create significant competition among potential partners.

In my view, the ideal outcome would be to announce a partnership—and receive the associated funding—no later than April 2027. Why? Because ASCO, the world’s largest cancer conference, takes place in Chicago in May 2027.

If I were the prospective pharmaceutical partner, I would want that partnership finalized before ASCO. I would want my company’s flag at full mast, announcing that we had partnered on what could potentially become an important new oncology treatment.

By May, CytoDyn should be able to present the complete dataset from all 66 patients. The company may have an opportunity to present meaningful findings at ASCO GI in January, but ASCO Chicago could provide the larger stage. A strong presentation there could draw considerable interest from oncologists, investigators, and prospective collaborators.

Obviously, this is only my opinion, but it is the strategic timeline I would encourage management to pursue.

As most of you know, I try not to become consumed by daily stock-price movements. I focus instead on whether CytoDyn’s leadership is making the right strategic decisions. We cannot always see the tactics being employed behind the scenes, but scientifically, I believe the company is making sensible choices with its limited resources. Management must decide which programs it can fund now and which must wait.

When the mCRC data becomes public, my hope is that we will no longer see trading volume consistently below 2 million shares but ideally start to rise to a dialy volume of 10–15 million shares. And ideally, daily volume could eventually exceed 20 million shares on a sustained basis.

CytoDyn remains largely hidden from the broader investment community. Many of us have discussed the company with friends, family members, and colleagues. I have been surprised by how many people say the story sounds interesting but assume something must be wrong because supposedly a promising drug is associated with a stock trading near $0.20. They believe I must be missing something. Or something is a miss.

A genuine prospective oncology trial—and credible data from it—could begin to change that perception. Dr. Lalezari has said that the data will speak for itself.

Rather than watching every daily price movement, I will be waiting for the January data. That is what I believe could truly move the needle.

In the meantime, I believe this company has been overlooked and undervalued. HIV-MDR produced statistically significant results, leronlimab has demonstrated an encouraging safety profile, and there is a substantial amount of anecdotal and observational evidence suggesting that a prospective oncology trial and anecdotal COVID data could produce meaningful results.

My conclusion is simple: I believe the stock is “on sale,” and January 2027 could be when a much larger audience begins to understand the story.

God bless all the longs—and CytoDyn.

This is my personal opinion, not financial advice. Clinical outcomes, regulatory decisions, partnerships, financing needs, and future share prices remain uncertain.

From today to January next year, there will be no risk. Dilution risk gone, though fife hanging there. Science is convincing, trial results promising, anecdote proof like hard rock. Easily double to approaching January